Literature DB >> 24739984

Two decades of successes and failures in controlling the transmission of HIV through injecting drug use in England and Wales, 1990 to 2011.

V D Hope1, R J Harris, D De Angelis, S Croxford, A Marongiu, J V Parry, F Ncube.   

Abstract

Responses to injecting drug use have changed focus over the last 20 years. Prevalence and incidence of human immunodeficiency virus (HIV) among people who inject drugs (PWID) in England and Wales were examined in relation to these changes. A voluntary unlinked-anonymous surveillance study obtained a biological sample and questionnaire data from PWID through annual surveys since 1990. Prevalence and incidence trends were estimated via generalised linear models, and compared with a policy time-line. Overall HIV prevalence among 38,539 participations was 1.15%. Prevalence was highest among those who started injecting before 1985; throughout the 1990s, prevalence fell in this group and was stable among those who started injecting later. Prevalence was higher in 2005 than 2000 (odds ratio: 3.56 (95% confidence interval (CI) 1.40–9.03) in London, 3.40 (95% CI 2.31–5.02) elsewhere). Estimated HIV incidence peaked twice, around 1983 and 2005. HIV was an important focus of policy concerning PWID from 1984 until 1998. This focus shifted at a time when drug use and risk were changing. The increased incidence in 2005 cannot be ascribed to the policy changes, but these appeared to be temporally aligned. Policy related to PWID should be continually reviewed to ensure rapid responses to increased risk.

Entities:  

Mesh:

Year:  2014        PMID: 24739984     DOI: 10.2807/1560-7917.es2014.19.14.20762

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  5 in total

1.  HIV seroprevalence in five key populations in Europe: a systematic literature review, 2009 to 2019.

Authors:  Annemarie Rinder Stengaard; Lauren Combs; Virginie Supervie; Sara Croxford; Sarika Desai; Ann K Sullivan; Stine Finne Jakobsen; Quenia Santos; Daniel Simões; Jordi Casabona; Jeffrey V Lazarus; John B F de Wit; Frank M Amort; Anastasia Pharris; Lina Nerlander; Dorthe Raben
Journal:  Euro Surveill       Date:  2021-11

2.  Epidemiology of HIV infection and associated behaviours among people who inject drugs in England, Wales, and Northern Ireland: Nearly 40 years on.

Authors:  Sara Croxford; Eva Emanuel; Ammi Shah; Cuong Chau; Vivian Hope; Monica Desai; Samreen Ijaz; Justin Shute; Claire Edmundson; Ross J Harris; Valerie Delpech; Emily Phipps
Journal:  HIV Med       Date:  2022-03-30       Impact factor: 3.094

3.  The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011-2018.

Authors:  Megan Bardsley; Ellen Heinsbroek; Ross Harris; Sara Croxford; Claire Edmundson; Vivian Hope; Nasra Hassan; Samreen Ijaz; Sema Mandal; Justin Shute; Sharon J Hutchinson; Matthew Hickman; Katy Sinka; Emily Phipps
Journal:  J Viral Hepat       Date:  2021-07-29       Impact factor: 3.517

4.  Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales: Results From Cross-Sectional Prevalence Surveys, 1992-2013.

Authors:  Vivian D Hope; Ross Harris; Jim McVeigh; Katelyn J Cullen; Josie Smith; John V Parry; Daniela DeAngelis; Fortune Ncube
Journal:  J Acquir Immune Defic Syndr       Date:  2016-03-01       Impact factor: 3.731

5.  A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs.

Authors:  Vivian D Hope; Ross J Harris; Peter Vickerman; Lucy Platt; Justin Shute; Katelyn J Cullen; Samreen Ijaz; Sema Mandal; Fortune Ncube; Monica Desai; John V Parry
Journal:  Euro Surveill       Date:  2018-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.